Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16033278rdf:typepubmed:Citationlld:pubmed
pubmed-article:16033278lifeskim:mentionsumls-concept:C0040300lld:lifeskim
pubmed-article:16033278lifeskim:mentionsumls-concept:C1955862lld:lifeskim
pubmed-article:16033278lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16033278pubmed:issue15lld:pubmed
pubmed-article:16033278pubmed:dateCreated2005-7-21lld:pubmed
pubmed-article:16033278pubmed:abstractTextA series of 6,7-disubstituted 4H-1,2,4-benzothiadiazine 1,1-dioxides bearing a short alkylamino side chain in the 3-position were synthesized. These compounds were tested on rat pancreatic islets and on rat aorta rings. In vitro data indicated that in most cases substitution in the 6 and the 7 positions increased their activity as inhibitors of insulin secretion, while the myorelaxant potency of the drugs was maintained or enhanced according to the nature of the substituent in the 7-position. The presence of either chlorine or bromine atoms in the 6 and 7 positions did not improve the apparent selectivity of the drugs for the pancreatic tissue. By contrast, the introduction of one or two fluorine atoms, as well as the presence of a methoxy group in the 7-position, generated potent and selective inhibitors of insulin release. Radioisotopic and fluorimetric experiments performed with the most potent compound inhibiting insulin release (34, BPDZ 259, 6-chloro-7-fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide) confirmed that the drug activated K(ATP) channels. 34 was found to be one of the most potent and selective pancreatic potassium channel openers yet described.lld:pubmed
pubmed-article:16033278pubmed:languageenglld:pubmed
pubmed-article:16033278pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16033278pubmed:citationSubsetIMlld:pubmed
pubmed-article:16033278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16033278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16033278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16033278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16033278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16033278pubmed:statusMEDLINElld:pubmed
pubmed-article:16033278pubmed:monthJullld:pubmed
pubmed-article:16033278pubmed:issn0022-2623lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:PirotteBernar...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:NguyenQuynh-A...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:AntoineMarie-...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:LebrunPhilipp...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:BeckerBénédic...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:BoverieStépha...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:SebilleSophie...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:CounerotteSté...lld:pubmed
pubmed-article:16033278pubmed:authorpubmed-author:FrancottePier...lld:pubmed
pubmed-article:16033278pubmed:issnTypePrintlld:pubmed
pubmed-article:16033278pubmed:day28lld:pubmed
pubmed-article:16033278pubmed:volume48lld:pubmed
pubmed-article:16033278pubmed:ownerNLMlld:pubmed
pubmed-article:16033278pubmed:authorsCompleteYlld:pubmed
pubmed-article:16033278pubmed:pagination4990-5000lld:pubmed
pubmed-article:16033278pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:meshHeadingpubmed-meshheading:16033278...lld:pubmed
pubmed-article:16033278pubmed:year2005lld:pubmed
pubmed-article:16033278pubmed:articleTitle3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.lld:pubmed
pubmed-article:16033278pubmed:affiliationCentre de Recherche en Pharmacochimie des Substances Naturelles et Synthétiques, Laboratoire de Chimie Pharmaceutique, Université de Liège, 1 Avenue de l'Hôpital, B-4000 Liège, Belgium. P.deTullio@ulg.ac.belld:pubmed
pubmed-article:16033278pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16033278pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:16033278pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16033278lld:chembl